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PhosphatidylglucosideCeramide, cholesterol, and phosphatidic acid are major basic structures for cell membrane lipids. These
lipids are modiﬁed with glucose to generate glucosylceramide (GlcCer), cholesterylglucoside (ChlGlc), and
phosphatidylglucoside (PtdGlc), respectively. Glucosylation dramatically changes the functional properties
of lipids. For instance, ceramide acts as a strong tumor suppressor that causes apoptosis and cell cycle arrest,
while GlcCer has an opposite effect, downregulating ceramide activities. All glucosylated lipids are enriched in
lipid rafts or microdomains and play fundamental roles in a variety of cellular processes. In this review, we
discuss the biological functions and metabolism of these three glucosylated lipids.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Glucose is themost important component formost living organisms.
Hexoses—of which glucose is one example—evolved as energy sources
critical for life. The brain is the most metabolically active tissue in ani-
mals and depends exclusively on glucose as its fuel source. Tumors,
groups of cells that are metabolically defective, also require glucose
for cell growth.nsporter A12; α-GalCer, α-
e; BMP, bis-monoacylglycero-
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e,Wako-shi, Saitama 351-0198,
B.V. Open access under CC BY-NC-NDBesides being an energy source, glucose is utilized for membrane
glycerolipids synthesis. Moreover, it is metabolically converted to
L-serine, which serves as a precursor amino acid for the synthesis
of lipids, including phosphatidyl serine/ethanolamine and glyco-
sphingolipids (GSLs) [1]. In mammals brain, L-serine is synthesized
and released into the extracellular space by astrocytes and radial
glia cells but not by neurons [2,3], indicating that L-serine is essential
for developing neurons.
Glucose is metabolically converted to uridine diphosphate
(UDP)-glucose, which is used as a lipid head group. To date, three
glucosylated lipids—glucosylceramide (GlcCer), cholesterylglucoside
(ChlGlc), and phosphatidylglucoside (PtdGlc)—have been iden-
tiﬁed in mammalian cell membranes [4]. Intriguingly, these three
glucosylated lipids are enriched in lipid rafts/lipid microdomains,
indicating that lipid glucosylation plays fundamental roles in
a variety of cellular processes. In fact, UDP-glucose ceramide
glucosyltransferase (UGCG), the key enzyme in glucosylceramide
synthesis, exists in essentially all animal tissues [5,6]. The high de-
gree of UGCG gene conservation across multicellular organisms
further emphasizes the biological signiﬁcance of glucosylated lipids.
In fact, knocking out the Ugcg gene in mouse and Drosophila results
in embryonic death.
In this review, we summarize new ﬁndings of studies on the
synthesis and the degradation of GlcCer and related lipids such as
ChlGlc and PtdGlc. New insights are derived. We emphasize that
although glucosylated lipids have simple structures, their functions
are critical for cellular homeostasis and basic cellular activities.
Glucosylated lipids are not simply precursor lipids for the synthesis
of complex glycolipids, as previously thought. license.
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2.1. Structure of GlcCer
GlcCer is a fundamental GSL found in organisms ranging from
mammals to fungi. It is composed of a hydrophilic β-linked glucose
and a hydrophobic ceramide. Mammalian GlcCer mainly contains
sphingosine (d18:1), a sphingoid base that has one double bond at
the C4 position in a trans conformation, and N linked C16–C24 fatty
acids (Fig. 1A). The N-acyl chain distribution varies among tissues
or cell types mainly due to differences in substrate speciﬁcity and ex-
pression patterns of ceramide synthases (CerS1–6) [7]. Fig. 1A shows
the acyl chain distribution of mono-hexosylceramide, which includes
GlcCer and galactosylceramide (GalCer), in brain, spleen, liver, kid-
ney, muscle, and adipose tissue of C57BL/6 mice. Do these differences
in ceramide moiety link to tissue speciﬁc functions?
Brennan et al. showed that GlcCer is a self-antigen that activates
invariant natural killer T (iNKT) cells [8], a subset of lymphocytes of
the innate immune system that have been reported to recognize
CD1d-bound glycolipid antigens such as α-galactosylceramide
(α-GalCer) or isogrobotrihexosylceramide (iGb3), both containing
α-linked galactose at non-reducing end [9,10]. Interestingly, activa-
tion efﬁciency of GlcCer depends on the composition of the N-acyl
chain. For example, C24:1 GlcCer, the predominant GlcCer in spleen
(Fig. 1A), effectively activates iNKT cells. This suggests that the
ceramide species play an important role in conveying the biological
activity of any given GlcCer.
In addition, a unique GlcCer, designated as epidermoside, was iso-
lated from mammalian epidermis [11]. Epidermoside is composed of
an amide-linked ω-hydroxy fatty acid and an ester-linked fatty acid
(Fig. 1B). Ceramides are the major component of the stratum corneum,
and form extracellular lamellar essential for epidermal permeability
barrier [12]. Importantly, epidermal ceramides are mainly generated
from GlcCer including epidermoside [13], which are packed into lamel-
lar granule in keratinocyte and transported to extracellular lamellar
[14]. ATP-binding cassette transporter A12 (ABCA12) is a keratinocyte
transmembrane lipid transporter that localizes at lamellar granule
[15,16]. The dysfunction of ABCA12 causes the reduction of epidermal
ceramides, malformation of the epidermal lipid barrier, and ichthyosis
phenotypes [15,16]. Interestingly, Mitsutake et al. suggested that
ABCA12 may function as a GlcCer transporter that translocates GlcCer
to the inner leaﬂet of lamellar granule [17]. Although there was no
supporting evidence to show the GlcCer-transporting activity in vitro,
they found that ABCA12-deﬁcient keratinocyte impairs the packing of
GlcCer in lamellar granule, resulting in the defect in ceramide genera-
tion [17].
Species-speciﬁc differences exist in the ceramide backbone structure
of GlcCer in plants, fungi, ﬂies, and worms (Fig. 1C). In plants, GlcCer
mainly contains a cis-double bond at the C8 position of its sphingoid
base [18] (Fig. 1C). The plant sphingolipid Δ-8-desaturase is a stereo-
unselective enzyme that catalyzes not only trans- but cis-double bonds
[19]. Plant GlcCer usually contains an α-hydroxylated fatty acid. Inter-
estingly, oral administration of plant GlcCer improves skin barrier
function by upregulating genes associated with tight junction and
corniﬁed envelope formation [20]. Fungal GlcCer has unique structural
features, including two double bonds at C4 and C8 in the trans
conformation and a methyl substituent on C9 in the sphingoid base
(Fig. 1C, [21]). The gene encoding sphingolipid 9-methyltransferase is
found only in fungi [22]. C16 and C18 α-hydroxylated fatty acids are
linked to this characteristic sphingoid base. GlcCer of ﬂies contains
a shorter chain sphingoid base (d14:1) (Fig. 1C) [23]. In mammals, the
ﬁrst step in ceramide biosynthesis is the condensation of L-serine and
palmitoyl-CoA to form 3-ketosphinganine by serine palmitoyl transfer-
ase (SPT). This reaction results in the formation of a sphingoid base
with C18 chain length. Insect and worm biosynthesis may be different.
In insect SPT, there may be a preference for dodecanoyl-CoA (C12 fattyacyl-CoA), forming a major C14 sphingoid base. C20:0 and C22:0 are
major fatty acids of GlcCer in Drosophila melanogaster [24]. GlcCer of
worms contains a C15-methyl-substituted sphingoid base (d17:1) and
α-hydroxylated C20–C26 fatty acids (Fig. 1C) [25].
2.2. Biosynthesis of GlcCer
2.2.1. Structure and localization of GlcCer synthase
GlcCer is synthesized by GlcCer synthase (UDP-glucose:ceramide
glucosyltransferase; UGCG, GlcT-1, CGT, or GCS, EC 2.4.1.80) from cer-
amide and UDP-glucose (Fig. 2A). The ugcg gene was ﬁrst isolated by
an expression cloning technique using ugcg-deﬁcient mouse melanoma
cells [26]. The gene is ubiquitously expressed in most mammalian
tissues. The molecular mass of rat/mouse UGCG is approximately
38 kDa on SDS-PAGE, although the value calculated from its cDNA
sequence is around 45 kDa (394 amino acid residues). No posttransla-
tional modiﬁcations of UGCG, such as N-glycosylation, O-glycosylation,
O-GlcNacylation, or acetylation, have been found. Proteome-wide quan-
tiﬁcation analysis of endogenous lysine ubiquitylation sites revealed that
lysines at 44, 49, 57, 104, and 124 of UGCG are ubiquitinated in HEK293
cells [27]. However, the signiﬁcance of the ubiquitination in UGCG is as
yet unclear. Rat UGCG forms a dimer or oligomer with another protein
[28]. Binding partners include c-Fos protein and RTN-1C, a reticulon
family protein; these activate the enzymatic activity of UGCG [29,30].
These binding protein partners, however, are not essential for UGCG ac-
tivity, because human UGCG expressed in Escherichia coli is active [26].
The 193 histidine residue of UGCG is involved in the binding of both
UDP-glucose and the enzyme inhibitor o-1-phenyl-2-decanoylamino-
3-morpholino-1-propanol (D-PDMP) [31]. Although UGCG belongs
to glycosyltransferase family (GTF) 21 [32], alignment of deduced
amino acid sequences revealed that the active site motif (D1, D2, D3,
and (Q/R)XXRW) in GTF2 is conserved in UGCG [33]. This enzyme is a
type III membrane protein that contains a single putative transmem-
brane domain at its N terminus, with its C terminus located in the cyto-
solic face of the Golgi apparatus [5,28,34]. The active site of this enzyme
faces the cytosol; thus, GlcCer is synthesized on the cytosolic surface of
the Golgi apparatus (Fig. 2B). In addition to mammalian UGCG, fungal,
plant, and insect UGCG also have been identiﬁed [6]. All of them share
a conserved amino acid sequence and an N-terminal transmembrane
domain.
Whereas mammalian UGCGmainly localizes in the Golgi apparatus,
D. melanogaster UGCG (dGlcT-1) localizes to both the Golgi and ER [35].
Althoughmammals, fungi, and Drosophila have only one gene encoding
ugcg, Caenorhabditis elegans has three genes, each of which encodes the
active form of UGCG [36]. In plant cells, a sterol glucoside-dependent,
UDP-glucose-independentGlcCer synthesis pathway is possibly present
in addition to the UGCG-dependent pathway [37].
2.2.2. Ceramide transport protein (CERT) and GlcCer synthesis
For the synthesis of GlcCer and sphingomyelin, ceramide must be
transported from the ER to Golgi compartments, because de novo syn-
thesis of these sphingolipids occurs in theGolgimembranes inmamma-
lian cells [38] (Fig. 2B). The major transport pathway between cellular
organelles is the budding and fusion of membrane vesicles [39]. An al-
ternative transport pathway involves CERT, a protein factor responsible
for non-vesicular transport of ceramide [40]. CERT contains a pleckstrin
homology (PH) domain that binds phophatidylinositol-4-phosphate
(PtdIns(4)P), a serine repeat motif, two phenylalanines in an acidic
tract (FFAT) motif that binds to vesicle-associated membrane protein-
associated proteins (VAPs), the ER resident type II membrane protein,
and a steroidogenic acute regulatory protein-related lipid transfer
(START) domain that recognizes ceramide. CERT binds to Golgi-
abundant PtdIns(4)P and to ER resident protein VAPs, then transfers
ceramide from the ER to the trans-Golgi network at ER-Golgimembrane
contact sites (Fig. 2B) [41]. Sphingomyelin synthase (SMS) 1 and 2
transfer the phosphorylcholine head group from phosphatidylcholine
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[42,43]. The active site of Golgi-localized SMS1 is on the luminal side
of the Golgi apparatus. Once delivered to the Golgi apparatus from the
ER by CERT, ceramide translocates to the lumen, possibly by spontane-
ous transbilayer movement. It is then utilized for sphingomyelin
synthesis (Fig. 2B). In CERT-deﬁcient mutant cells, the level of
sphingomyelin, but not GlcCer, is reduced [44], supporting the role of
CERT in the delivery of ceramide destined for sphingomyelin synthesis.
Ceramide required for GlcCer synthesis is thought to be
transported from the ER to Golgi in a vesicle-dependent manner
[45,46]. The transport of very long chain fatty acids (C22–24)containing ceramide destined for GlcCer synthesis is regulated by
glycosylphosphatidylinositol (GPI) anchor molecules, important
protein-anchoring lipids [47]. Cells with a defect in the GPI-anchor
maturation system have decreased levels of very long chain GlcCer
molecules but normal sphingomyelin levels [48]. Indeed, correctly-
modiﬁed GPI anchor molecules have been proposed to act as signals
for ER exit by coat protein complex II (COPII) vesicles [49]. This
machinery may be involved in the transport of very long chain
ceramides to the Golgi.
These observations in ceramide transport raise the question of
why CERT-transported ceramide is speciﬁcally used for sphingomyelin
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transports ceramide to trans-Golgi regions where PtdIns(4)P and
SMS1 are present, while UGCG localizes at cis-Golgi regions or ER and
is unable to utilize CERT-transported ceramide. We have suggested
an alternative possibility. We found that PtdIns(4)P speciﬁcally
inhibited in vitro UGCG activity in a concentration-dependent manner,
while SMS activity was unaffected (manuscript in preparation). The
effect of PtdIns(4)P was overridden by increasing the concentration
of UDP-glucose in the reaction solution, suggesting that PtdIns(4)P
may inhibit contact between the active site of UGCG and UDP-glucose
(Fig. 3).
The interaction between PtdIns(4)P and the PH domain of CERT
is indispensable for the transport of ceramide from ER to Golgi [50].
Therefore, CERT-transported ceramide may colocalize with PtdIns(4)P,
thereby inhibiting, or interrupting, transfer of glucose from UDP-
glucose to ceramide by UGCG (Fig. 3). Supporting this notion is the
ﬁnding that the catalytic domains of UGCG and PtdIns(4)P both face
the cytosolic side of the Golgi membrane [28,51]. It is interesting to
know whether they functionally interact with each other in the Golgi
membrane.
2.3. Functions of GlcCer
From in vitro and in vivo studies, important roles of UGCG in de-
velopment and differentiation have been revealed. Knockout and/or
knockdown of UGCG are lethal in mouse, Drosophila, and C. elegans,
indicating a crucial role for GlcCer and GSLs synthesized from GlcCer
during embryogenesis [35,36,52,53]. Ugcg knockout mice die in utero,
because gastrulation is blocked by ectodermal apoptosis [53,54].
Several conditional knockout mice have been generated and carefully
studied. Examination of these conditional knockout mice revealed
that GlcCer synthesis has tissue-speciﬁc functions; some tissues re-
quire GlcCer synthesis, whereas others, like liver, do not. For a more
detailed discussion of GlcCer function, please see the following recent
review articles: [4,55]. In the present review, we focus on the role of
GlcCer, as revealed by invertebrate model animals.
2.3.1. Epithelial GlcCer in cell polarity
As mentioned above, the UGCG gene is highly conserved across
species. Three UGCG genes exist in C. elegans. Knockdown of all three
UGCG genes causes growth arrest at the ﬁrst larval stage [52]. It wasCeramide 
(CERT-transported
SM synthase
Ceramide 
(Vesicle-transported)
Fig. 3. Proposed mechanism explaining why CERT-tranrecently identiﬁed using a global C. elegans tubulogenesis screening
assay that UGCG is a critical enzyme for epithelial polarity [56]. GSLs
mediate apical sorting and speciﬁcally help to maintain apicobasal po-
larity in vivo. Depletion of sugar modiﬁcation genes that add sugars to
GlcCer failed to generate the polarity defect phenotype, indicating that
GlcCer is the glycolipid responsible for C. elegans tubulogenesis.
2.3.2. GlcCer in energy homeostasis
The Drosophila fat body is equivalent to adipose tissue and liver in
mammals, and is an important tissue for energy homeostasis in this
species. Since the biological system for energy metabolism and ho-
meostasis is evolutionarily conserved, Drosophila has become widely
used as a model for understanding the role of fat tissue in energy ho-
meostasis [57]. UGCG expression in the Drosophila fat body regulates
energy metabolism [24]. Overexpression of UGCG increases stored
nutrition (triacylglycerol and carbohydrate) levels. Conversely, reduced
expression of UGCG in the fat body causes a reduction of fat storage.
GlcCer is the sole GSL of the fat body, indicating that UGCG-associated
GlcCer synthesis in the fat body is responsible for regulating energy ho-
meostasis in the whole body.
Very recently, it has been reported thatUGCG in central nervous sys-
tem (CNS) regulates energy homeostasis [58]. The forebrain-neuron
speciﬁc deletion of UGCG in mice resulted in obesity, hypothermia,
and lower sympathetic activity. Using immortalized hypothalamic neu-
rons (N-41 cells), it has been shown that GlcCer-derived gangliosides
affect proper leptin receptor signaling. Although it is not clear whether
GlcCer itself plays an important role in this regulatory system, this study
demonstrated that UGCG expression in neurons of the adult CNS regu-
lates leptin signaling pathway and controls energy homeostasis in
whole animal level.
Taken together with the Drosophila study, these ﬁndings demon-
strate that the UGCG in central and peripheral organs is involved in
control of energy homeostasis, and suggest that manipulation of
UGCG activity could be a potential target for obesity therapy.
In ob/ob mice, an animal model of type II diabetes, GlcCer levels are
increased in several tissues, such as liver andmuscle. Interestingly, insu-
lin sensitivity, glucose homeostasis, and adipocyte function are improved
by treating themice with an UGCG inhibitor, such as N-(5-adamantane-
1-yl-methoxy-pentyl)-deoxynojirimycin (AMP-DNM) or N-[(1R,2R)-
1-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)
propan-2-yl]nonanamide (Genz-123346) [59,60]. These results furtherUDP-Glucose
)
Golgi apparatus
GlcCer synthase
sported ceramide is not used for GlcCer synthesis.
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homeostasis.
Ceramide also plays a role in insulin resistance [61]. However,
which is important in terms of modulator of energy homeostasis—
GlcCer or ceramide? Ceramide, rather than GSLs, is required for
blocking the activation of Akt/PKB in muscle [62–64]. On the other
hand, adipocytes are more sensitive to glucosylated sphingolipids
[59,65]. These studies demonstrate that ceramide and GlcCer have
tissue-speciﬁc functions in controlling energy homeostasis.
Lipid droplets (LDs) are themajor cellular organelle for the storage of
neutral lipids. Until recently, LDs were thought to be biologically inert.
However, LDs turn out to be extremely important for cell activities and
functions. LDs exist ubiquitously in most cells and have been implicated
in other cellular functions, such as protein storage and degradation [66].
LDs are believed to originate from the ER, although the exactmechanism
of their biosynthesis and growth remains to be elucidated. Phosphati-
dylethanolamine (PtdEth) and PtdCho are major components of most
LDs [67]. In addition to these lipids, sphingolipids are also present. The
role of sphingolipids in LD growth, however, is still not understood.
Drosophila has become a very useful model animal in LD biology
[68]. A growing number of studies on LDs using Drosophila have been
published, providing deep and new insight into understanding human
diseases, such as obesity and type II diabetes. Genome-wide RNAi
screening ofDrosophila tissue culture has revealed numerous regulators
of LD biogenesis and utilization [69]. Among these are COPI trafﬁcking
proteins, which are functionally conserved and regulate LDmorphology
in ﬂies and lipid utilization in mammals.
As discussed above, GlcCer exists in the LDs of the Drosophila fat
body. Drosophila with high GlcCer levels in the fat body has large
LDs, whereas the opposite is true for low GlcCer levels [24]. Whether
GlcCer synthesis has any functional link to COPI trafﬁcking proteins
is unknown. Further studies are needed to understand how GlcCer
regulates LD formation at the cytosolic surface membranes of the ER.
2.3.3. The function of fungal GlcCer
The functions of fungal GlcCer have been well investigated. Mor-
phological transitions such as budding and germ tube formation
are inhibited by GlcCer synthase inhibitors or anti-GlcCer antibodies
[70,71]. Immunoﬂuorescent microscopic analysis shows that GlcCer
concentrates at the site of budding cells during cell division [71,72].
While yeasts that synthesize GlcCer can survive at higher pHs, GlcCer
synthase-deﬁcient mutants are unable to grow [73], indicating that
GlcCer is involved in fungal cell growth and differentiation, especially
under alkali conditions.
Fungus-speciﬁc GlcCer is also thought to be important for the action
of plant defensin from Raphanus sativus antifungal peptides (RsAFPs)
[74]. RsAFP2 inhibits the growth of pathogenic fungi such as Candida
albicans and Pichia pastoris. However, GlcCer synthase-deﬁcient mutants
are resistant to RsAFP2. RsAFP2 interactswith fungus-speciﬁc GlcCer, but
not with plant or mammalian GlcCer. This suggests that the ceramide
moiety is important for the recognition of GlcCer by RsAFP2 (Fig. 1).
Most importantly, fungal GlcCer is required for the virulence of
pathogenic fungi to be expressed. Disruption of enzymes involved in
GlcCer biosynthesis reduces the pathogenicity of C. albicans [75] and
Cryptococcus neoformans [76,77], which is the common species causing
cryptococcosis, a life-threatening central nervous system infection [78].
Thus, targeting the metabolic pathway of fungus GlcCer has become a
new therapeutic strategy for the treatment of fungal infections, because
the pathway contains fungus-speciﬁc enzymes such as sphingolipid
9-methyltransferase.
2.4. Regulation of GlcCer synthase activity
2.4.1. Transcriptional regulation of ugcg
Because mammals have only one gene encoding ugcg, changes in
ugcg mRNA expression levels are critical for determining intracellularGlcCer levels. Previous reports indicate that several compounds can
alter ugcg mRNA expression levels. Treatment with the endotoxin
lipopolysaccharide (LPS), which mimics Gram-negative infections,
increases GlcCer levels and ugcg mRNA expression in mouse bone-
marrow-derived dendritic cells (BMDCs) [8] and in liver, spleen, and
kidney in Syrian hamsters [79,80]. GlcCer is a potent self-antigen that
activates iNKT cells [8]. Thus, the LPS-induced accumulation of GlcCer
is thought to represent an innate danger signal for microbial infections.
Polycystic kidney disease (PKD) is one of themost common genetic
disorders accompanied by renal cystic growth and massive kidney
enlargement [81]. GlcCer and ganglioside GM3 levels in kidney are in-
creased in PKD patients andmousemodels of PKD [82]. Since the inhi-
bition of UGCG activity effectively prevents cystogenesis in mouse
models of PKD, the accumulation of GSLs is believed to be an impor-
tant factor contributing to disease progression. Although the precise
mechanism is unknown, ugcg mRNA is overexpressed in kidney cells
derived from mouse models of PKD [82].
The expression of ugcg mRNA is signiﬁcantly increased in tumors
of the breast (particularly in metastatic carcinoma), small intestine,
cervix, and rectum compared to that in normal human tissues [83].
Ugcg overexpression is associated with drug resistance in several can-
cer cells and the maintenance of pluripotency in breast cancer stem
cells [84,85]. Treatment of drug-sensitive cancer cells with the anti-
cancer drug doxorubicin induces an increase in ceramide, which
drives apoptosis and cell cycle arrest [86]. In drug-insensitive cancer
cells, the tumor-suppressing effect of ceramide is counteracted by
its rapid conversion into GlcCer, which is mediated by overexpressed
UGCG [87]. Although the ugcg promoter region lacks TATA and CAAT
boxes, it contains some transcription-factor recognizing sites such as
Sp1 binding sites, which are indicators of typical housekeeping genes
[88]. It also contains the motifs for AhR, NF-kB/C-Rel, AP-2, CAP,
and GATA-1 binding sites [89]. In doxorubicin-treated cancer cells,
Sp1-mediated transcription of ugcg mRNA is upregulated [90,91].
Suppression of UGCG expression by siRNA and inhibition of UGCG ac-
tivity sensitize cancer cells to anticancer agents [86]. These ﬁndings
suggest that UGCG could be a potential target for cancer therapy.
2.4.2. Post-translational regulation of UGCG
Mutations in presenilin 1, an essential component of the γ-secretase
complex [92], are associated with early onset familial Alzheimer's
disease. These mutations result in the preferential deposition of patho-
genic amyloid β. Interestingly, the UGCG protein expression is reduced
inmutant presenilin 1-transfected neuronal cells, butmRNA expression
is unaffected [93]. Correspondingly, the amounts of GlcCer and ganglio-
side, which is synthesized from GlcCer, are signiﬁcantly decreased in
these cells. Reduction of neuroprotective ganglioside probably makes
the neurons vulnerable to cellular stresses, including the deposition of
amyloid β. The precisemechanismbywhichmutant presenilin 1 causes
the reduction in UGCG protein expression is unclear. We predict that
some abnormalities in the ubiquitin–proteasome pathway may be in-
volved in this phenomenon, because UGCG has multiple ubiquitination
sites in its cytoplasmic domain [27].
2.4.3. Regulation of GlcCer synthase activity by AMPK
The hydrolysis of ATP drives all energy-requiring processes in living
cells. To maintain ATP at a sufﬁcient level, eukaryotic cells have an
important nutrient and energy sensor, AMP-activated protein kinase
(AMPK) [94]. AMPK is a heterotrimeric serine/threonine kinase that
promotes ATP-generating pathways, such as glycolysis or fatty acid
oxidation, while inhibiting anabolic processes, such as biosynthesis
of fatty acids, cholesterol, glycogen, and triacylglycerol under energy
reducing conditions (i.e., increasing AMP/ATP or ADP/ATP ratios).
Recently, we found that AMPK also affects the biosynthesis path-
way of GlcCer (manuscript in preparation). Intracellular GlcCer levels
and UGCG activity were reduced by AMPK activating drugs, such
as 5-aminoimidazole-4-carboxamide 1-β-D-ribofuranoside (AICAR)
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inhibitors or AMPK siRNA overrode the reduced GlcCer synthase
activity or cellular GlcCer levels under AMPK-activating conditions,
indicating that AMPK is a negative regulator of GlcCer synthesis.
UGCG protein and mRNA expression were unchanged under AMPK-
activating and AMPK-inhibiting conditions. It is important to under-
stand the molecular mechanism by which GlcCer levels are controlled
by AMPK.
2.5. Degradation of GlcCer
2.5.1. Mammalian GCases
GlcCer is degraded by the detachment of glucose from GlcCer
by glucocerebrosidase (GCase or also called glucosylceramidase,
EC3.2.1.45). In mammals, catabolism of GlcCer mainly takes place in
lysosomes by acid-GCase (GBA1), with the assistance of saposin C
(SAP-C), a sphingolipid activator protein, and negatively charged
lipid bis-monoacylglycero-phosphate (BMP) [95]. GBA1 is sorted
to lysosomes by binding with lysosomal integral membrane protein
type 2 (LIMP-2) [96,97]. GBA1 is a water soluble, positively charged
glycoprotein that can attach to lysosomal membranes by interacting
with BMP. SAP-C activates GBA1 by mediating the interaction be-
tween the substrate and the enzyme [98,99].
A deﬁciency in GBA1 activity due to biallelic mutations in the Gba1
gene leads to the most common inherited sphingolipidosis, Gaucher
disease. In this patient, GlcCer accumulates in lysosomes of macro-
phages, causing liver and spleen enlargement, and impairment of the
central nervous system [100]. Very interestingly, in addition to Gaucher
disease, GBA1 mutations represent a genetic risk factor for developing
insulin resistance [101] and synucleinopathies such as dementia
with Lewy bodies (DLB) and Parkinson's disease [102,103]. Mazzulli
et al. reported that the accumulation of GlcCer due to GBA1 dysfunction
inﬂuences the formation of neurotoxic amyloid of α-synuclein in lyso-
somes [104].
The abnormal accumulation of GlcCer is linked to several human
diseases. To counter the toxic effects of GlcCer, mammalian cells
possess multiple GlcCer-degrading enzymes, in addition to GBA1, to
tightly regulate intracellular GlcCer levels. GBA1 is speciﬁcally and
irreversibly inhibited by conduritol B epoxide (CBE) [105]. GBA2 is a
CBE-insensitive, non-lysosomal GCase that hydrolyzes not only GlcCer
but also bile acid-3-O-β-glucoside [106,107]. GBA2 is a non-integral
membrane protein that localizes at the cytosolic surface of ER and
Golgi, where it is in close associationwithmembranous phospholipids
[108]. Based on its localization and topology, GBA2 is thought to con-
trol the amount of newly synthesized cytosolic GlcCer.
Human and mouse studies have revealed the physiological impor-
tance of GBA2. Although Gba2 knockout mice exhibit normal bile acid
metabolism, GlcCer accumulates in multiple tissues, including testis,
liver, and brain [106]. Therefore, at least in these tissues, this suggests
that GBA2 mainly functions as a GlcCer-degrading enzyme in vivo.
Accumulation of GlcCer due to GBA2 deﬁciency leads to impaired
male fertility as a result of aberrant sperm formation [106]. Delay of
liver regeneration after partial hepatectomy has also been reported
in these mice [109].
GBA2 activity is reduced in cells from Gba1-deﬁcient Gaucher dis-
ease patients, suggesting that GBA2 may also be involved in the patho-
genesis of Gaucher disease [108]. Moreover, Gba2mutations are found
in some neurodegenerative disorders, such as autosomal-recessive
cerebellar ataxia (ARCA) and hereditary spastic paraplegias (HSPs)
[110,111]. Human genetic studies strongly suggest that dysfunction of
GBA2 probably affects the progression of ARCA and HSPs [110,111].
As described above, the overexpression of UGCG confers drug re-
sistance to cancer cells by reducing ceramide, an apoptosis-inducible
lipid mediator. GBA2, on the other hand, has anticancer activity that
results in the generation of ceramide at ER and promotes ER stress
and apoptosis [112]. The GBA2-mediated GlcCer catabolic pathway isexpected to be a fruitful avenue to focus on for new diagnostics or
new therapeutics for these diseases.
GBA3, also known as Klotho-related protein (KLrP) [113], is a
CBE-insensitive cytosolic GCase [114]. The function of GBA3 is largely
unknown, but at least, it seems to have little inﬂuence on the mani-
festation of Gaucher disease [115].
Lactase phlorizin hydrolase, which is exclusively present in the
plasma membrane of the small intestine, is thought to be involved in
the digestion of dietary GlcCer, lactose, and other glucose-containing
compounds [116]. It is a transmembrane protein with two active sites
located on the luminal side [117,118].
2.5.2. Fungal GCase
As shown in Fig. 1, fungi synthesize a fungus-speciﬁc GlcCer that
contains a unique sphingoid base possessing two double bounds
and a methyl substitution (methyl d18:2). Correspondingly, fungi
possess a fungus-speciﬁc GCase, designated as EGCrP1 [119]. This
enzyme is listed in several fungal genomic databases as a homolog
of endoglycoceramidase, which cleaves the ceramide-glucosidic link-
age of various GSLs to release free oligosaccharide and ceramide
[120–122]. Recombinant EGCrP1 speciﬁcally hydrolyzes GlcCer but not
other GSLs. Disruption of egcrp1 in the pathogenic fungus C. neoformans
leads to the accumulation of immature GlcCer, which has sphingoid
bases lacking a methyl substitution and double bonds [119]. This obser-
vation indicates that EGCrP1 participates in the catabolism of GlcCer
and especially functions to eliminate immature GlcCer generated as
byproducts due to the broad speciﬁcity of UGCG.
Several reports have indicated that fungus-speciﬁc GlcCer possessing
a methyl d18:2 sphingoid base is biologically relevant, as described
above. By contrast, immatureGlcCer is unable to compensate for the func-
tions of fungus-speciﬁc GlcCer [75,77,123,124]. Ceramide maturation en-
zymes such as sphingolipid delta 4-desaturase and 9-methyltransferase
utilize ceramide, not GlcCer, as an acceptor substrate [22,125]. Thus,
once immature ceramide is converted to GlcCer, the process of matura-
tion is terminated, resulting in the accumulation of immature GlcCer.
EGCrP1 seems to convert the immature GlcCer to immature ceramide,
causing the maturation of GlcCer to proceed again [119].
3. Cholesterylglucoside
In 2000, Murofushi and co-workers ﬁrst isolated mammalian
glucosylated cholesterol (1-O-cholesteryl-β-D-glucopyranoside, ChlGlc)
from cultured TIG-3 ﬁbroblasts [126] and gastric mucosa [127] of
humans (Fig. 4). Interestingly, heat shock rapidly induces ChlGlc syn-
thesis followed by HSF1 activation and HSP70 induction in human
ﬁbroblasts [128]. In order to decipher the molecular mechanisms of
HSP70-induction by ChlGlc, it is essential to identify the enzyme re-
sponsible for ChlGlc formation. Akiyama et al. proposed that GlcCer is
a glucose donor for ChlGlc synthesis [129]. Supporting this notion is
the ﬁnding that UGCG-deﬁcient GM-95 cells are unable to synthesize
ChlGlc without the exogenous addition of GlcCer. ChlGlc may serve as
a heat-associated signaling platform or a heat-signal molecule for HSP
gene activation, but details of ChlGlc functions are as yet unknown.
4. Phosphatidylglucoside (PtdGlc)
4.1. Chemical structure and properties of PtdGlc
In 2001, Nagatsuka et al. reported the possible presence of a
glucose-containing glycerolipid in human cord blood cells [130]. Later
the same group found a similar glucosylated lipid in detergent-
insolublemembrane (DIM) fractions of human promyelocytic leukemia
cells [131]. However, the compound was in very low concentrations
and its structure was alkaline-labile. Thus, it was very difﬁcult to purify
PtdGlc to determine its complete structure. In 2006, Yamazaki et al.
generated a PtdGlc-speciﬁc monoclonal antibody termed DIM21 by
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studies using synthetic derivatives of PtdGlc showed that a hydroxyl
group at position 6 of the hexose ring and an ester group at sn−2
of arachidic acid are critical for antibody binding [133]. By using the
monoclonal antibody, PtdGlc was isolated from fetal rodent brains and
puriﬁed to homogeneity. Its complete structure was determined to be
1-stearyl-2-arachidoyl-sn-glycerol-3-phosphoryl-β-D-glucopyranoside
(Fig. 4).
Acetylated PtdGlc (1-stearyl-2-arachidoyl-sn-glycerol-3-phosphoryl
β-D-(6-O-acetyl)glucopyranoside) also exists in fetal rat brain [134]
(Fig. 4). Very interestingly and importantly, PtdGlc isolated from fetal
rat brain has only one fatty acid combination: the sn−1 and sn−2
chains are exclusively stearic acid (C18:0) and arachidic acid (C20:0),
respectively. A singlemolecular species rarely occurs in natural phospho-
lipids. Also, inmammals there are very fewnatural lipids that possess the
C20:0 acyl chain as their major component. It is also important to note
that PtdGlc from rat brain contains a PtdGlc stereoisomer with the phos-
phate group at the sn−1 position of glycerol.
4.2. Distribution
Expression of PtdGlc is developmentally regulated in the rodent
brain. PtdGlc is most strongly expressed in radial glia in early stages
of developing rat brains (E12.5–14.5). Neural stem cells (Type B) in
the subventricular zone continuously express PtdGlc. The glycolipid
is thought to be a good cell surface marker for stem cells [135].
PtdGlc is also found in various tissues of humans, indicating that it
has previously unrecognized important biological roles in mammals
[136]. Differentiated CD15-positive neutrophils contain PtdGlc [137].
In these cells, PtdGlc comprises C18:0/C18:0 and C18:0/C20:0 fatty
acyl chains [138].
4.3. Physical properties
Examination of the thermal behavior of synthetic PtdGlc through
differential scanning calorimetry (DSC) analysis shows that syntheticPtdGlc has a high main phase transition temperature of 76.4 °C [139].
This high temperature property is quite reasonable, since PtdGlc con-
sists of saturated long-chain fatty acids. Interestingly, DSC analysis
shows that PtdGlc is not miscible with sphingomyelin, even though
GlcCer is. In addition, PtdGlc is poorly miscible with PtdCho. These
physical properties suggest that PtdGlc forms distinct, PtdGlc-rich
lipid domains on plasma membranes (please see our recent review
for details [140]). Immunoelectron microscopy with DIM21 using the
SDS-digested freeze fracture replica labeling method demonstrated
that PtdGlc forms distinct lipid domains exclusively on the outer, not
inner, leaﬂet of the plasma membrane of HL60 cells and A549 cells, a
human alveolar epithelial cell line [139].
4.4. Possible roles of PtdGlc and its metabolites
The biological roles of PtdGlc remain to be elucidated. To this end,
we used DIM21 antibody as an artiﬁcial ligand and found that adding
DIM21 to cultured neural progenitor cells prepared from fetal mouse
telencephalon results in the recruitment of EGF receptors into
PtdGlc-rich lipid rafts, leading to the activation of EGF receptors
[141]. In human neutrophils, DIM21 treatment induced Fas clustering,
leading to Fas-dependent apoptotic cell death [138]. This suggests
that the Fas-receptor is associated with lipid rafts composed of PtdGlc
on neutrophil plasma membranes.
Although its physical properties are similar to GlcCer, PtdGlc is
clearly different from GlcCer in that its acyl chain is easily cleaved
by phospholipases, like PLA2, to become water-soluble lyso-PtdGlc.
In mammals, the enzyme that converts GlcCer to lyso-GlcCer is yet
to be identiﬁed. Lyso-PtdGlc has strong growth cone collapse activities
in cultured mouse DRG neurons [4]. Like other lyso-phospholipids,
such as lyso-phosphatidic acid (LPA) and lyso-PtdEth (LPE), lyso-
PtdGlc also may have signiﬁcant biological functions in vivo. It would
also be interesting to determine whether a PtdGlc-speciﬁc phospholi-
pase or preferential phospholipases like phosphatidylinositol (PtdIns)-
speciﬁc PLC also exist.
How PtdGlc is biosynthesized remains unknown. Our preliminary
studies indicated that the PtdGlc biosynthesis is UDP-glucose dependent
and occurs in luminal ER membranes. Thus, the biological signiﬁcance
of lipid glucosylation of GlcCer and PtdGlc must be different. Future
study is necessary to identify the gene responsible for glucosylation of
phosphatidic acid (PtdAc).
The role of O-acetylation of PtdGlc at the C6 position of its glucose
ring remains unclear. The acetylated lipid may be immunogenic and
have its own biological function. The presence of an O-acetylated glu-
cose residue may reﬂect the metabolic state of cells, since acetyl CoA
must be incorporated into luminal ER by acetyl CoA transporter
(AT-1) in the ER membrane (for details, please see review [142]).
5. Concluding remarks
All three glucosylated membrane lipids discussed in this review
have conserved biological functions. It is of particular interest that
GlcCer synthesis regulates the accumulation and release of stored tri-
glycerides in the fat body of Drosophila and adipose tissue of mammals.
The regulatory role of GlcCer in energy homeostasis is not surprising,
because the basic building blocks of GlcCer synthesis, namely UDP-
glucose, palmitoyl-CoA, and L-serine (derived from glucose), are direct-
ly related to energymetabolism. From this point of view, it is reasonable
that UGCG can sense the energy state of a cell, since the transfer of glu-
cose from UDP-glucose produced in the cytosol occurs in the cytosolic
but not the luminal side of Golgi membranes.
In the case of GlcCer, differentGlcCer species exist in different organ-
isms. Even within the same organism, different GlcCer species exist in
different tissues. These differences are due to variations in the sphingo-
sine base and fatty acyl chain compositions of different GlcCer species.
Therefore, it would be reasonable to conclude that each GlcCer species
1483Y. Ishibashi et al. / Biochimica et Biophysica Acta 1831 (2013) 1475–1485may have speciﬁc and unique, yet far-reaching, biological functions, as
proposed by Hannun and Obeid [7].
In contrast to GlcCer, PtdGlc and ChlGlc are simple in their hydro-
phobic moiety. PtdGlc contains only saturated fatty acids (18:0 and
20:0). Based on its physical properties, PtdGlc is thought to form spe-
ciﬁc lipid microdomains or lipid rafts on the outer leaﬂet of plasma
membranes. Products from PtdGlc degradation are also expected to
act as second messengers and/or signaling molecules functioning in
cell–cell communication.
Molecular cloning of the gene that encodes the synthetic enzyme
that glycosylates PtdAc to generate PtdGlc is an essential step to better
understand the in vivo roles of PtdGlc. Advanced MS technology abso-
lutely will accelerate this process, helping us to gain a more in-depth
understanding of the roles of glucosylated lipids. However, one must
be careful in using high-throughput approaches to identify PtdGlc and
its metabolites, since the total mass number of PtdGlc is identical to
that of the more abundant membrane component, PtdIns [143]. We
expect that further investigations of simple monoglucosylated lipids
will open a new chapter in membrane lipid biology and glycobiology.
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